Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
ImmuneOnco Biopharmaceuticals (Shanghai) Inc Class H ( (HK:1541) ) has provided an update.
ImmuneOnco Biopharmaceuticals (Shanghai) Inc. has received approval from China’s National Medical Products Administration to initiate a clinical trial of its core drug candidate IMM01 (Timdarpacept) for the treatment of atherosclerosis, marking an expansion of the molecule’s development beyond oncology into cardiovascular disease. The CD47‑targeting SIRPα‑Fc fusion protein, already in clinical use in China and granted U.S. orphan-drug designation in combination with azacitidine for first-line treatment of chronic myelomonocytic leukemia, has been engineered for a favorable safety profile through selective macrophage activation and avoidance of red blood cell binding; the new trial underscores the company’s effort to broaden therapeutic indications and leverage its globally protected asset, although management cautions there is no guarantee IMM01 will be successfully developed or commercialized.
The most recent analyst rating on (HK:1541) stock is a Hold with a HK$6.50 price target. To see the full list of analyst forecasts on ImmuneOnco Biopharmaceuticals (Shanghai) Inc Class H stock, see the HK:1541 Stock Forecast page.
More about ImmuneOnco Biopharmaceuticals (Shanghai) Inc Class H
ImmuneOnco Biopharmaceuticals (Shanghai) Inc. is a China-based biopharmaceutical company focused on developing innovative immunotherapies, with a core emphasis on CD47-targeting molecules such as its lead asset IMM01 (Timdarpacept). The group holds global intellectual property and commercial rights to IMM01, including an international patent family covering major markets such as China, the United States, Japan and the European Union, reflecting its ambitions in both domestic and global oncology and immune-related disease markets.
Average Trading Volume: 1,858,871
Technical Sentiment Signal: Sell
Current Market Cap: HK$5.16B
Find detailed analytics on 1541 stock on TipRanks’ Stock Analysis page.